Introduction to Beligas Pharmaceuticals: Beligas Pharmaceuticals, headquartered in Belgium, has established itself as a leader in the pharmaceutical and biotechnology sectors. Founded through a collaboration between Allied Research in Belgium and Greenpine Pharmaceuticals in China, Beligas leverages advanced technology and extensive facilities in East Asia to produce high-quality pharmacological substances. Their product portfolio includes human growth hormones, anabolic steroids, peptides, and other essential medicines aimed at enhancing the quality of life for individuals globally.

Historical Milestones: Beligas achieved a significant milestone in 2014 by concluding the phase 1 clinical trial for the first growth hormone frag 191+ in Europe. This positioned Beligas among the top-tier biosimilar developers. Their continuous focus on R&D has led to the development of more effective peptides and potent human growth hormones.

Global Reach and Expansion: With a strong financial and operational base, Beligas is actively expanding its presence in the global pharmaceutical market, making its products available worldwide through a network of trusted partners and distributors.